Home LiteratureArticle Details
PMID: 2939795 Published · ppublish English Journal Article

Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria.

Antimicrobial agents and chemotherapy ·Vol. 28 ·No. 2 ·1985-08-00 ·Pages 308-10

Eron LJ, Harvey L, Hixon DL, Poretz DM

Abstract

Ciprofloxacin was administered orally to 48 patients with 24 Pseudomonas aeruginosa infections and 13 other infections caused by cephalothin-resistant gram-negative bacilli. The types of infections treated included those of skin or skin structure, bone, urinary tract, and respiratory tract. In 83% of P. aeruginosa infections, a favorable clinical outcome occurred, compared with 85% for all infections. Failure to achieve a cure correlated with the emergence of resistant P. aeruginosa and Acinetobacter calcoaceticus strains in four instances and superinfection with Candida (two cases) and Streptococcus (two cases) species. Therapy was discontinued in three patients because of the development of nausea. Ciprofloxacin appears to be safe and effective in the therapy of infections caused by resistant gram-negative bacilli.

MeSH Terms
Administration, Oral Adult Aged Bacterial Infections/drug therapy Ciprofloxacin Drug Resistance, Microbial Female Humans Male Middle Aged Nausea/chemically induced Pseudomonas Infections/drug therapy Quinolines/administration & dosage,adverse effects,therapeutic use
Chemicals
Quinolines Ciprofloxacin
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Eron L J
Harvey L
Hixon D L
Poretz D M
References (10)
10 references, click to expand
  1. Tobramycin sulfate: a summary of worldwide experience from clinical trials.
    J Infect Dis. 1976 Aug;134 Suppl:S219-34 PMID: 787450
  2. Clinical trial of piperacillin with acquisition of resistance by Pseudomonas and clinical relapse.
    Antimicrob Agents Chemother. 1980 Jul;18(1):167-70 PMID: 6448020
  3. Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy.
    Antimicrob Agents Chemother. 1981 Sep;20(3):351-5 PMID: 6458233
  4. Clinical experience with Moxalactam in the treatment of pseudomonal and nonpseudomonal infections.
    Antimicrob Agents Chemother. 1982 Apr;21(4):568-74 PMID: 6211137
  5. A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam.
    Eur J Clin Microbiol. 1984 Oct;3(5):478-87 PMID: 6389126
  6. Piperacillin therapy for Pseudomonas infections.
    South Med J. 1983 Jul;76(7):859-62 PMID: 6223378
  7. Ceftazidime in patients with Pseudomonas infections.
    J Antimicrob Chemother. 1983 Jul;12 Suppl A:161-9 PMID: 6225762
  8. Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms.
    Antimicrob Agents Chemother. 1983 Aug;24(2):176-80 PMID: 6357068
  9. In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.
    Antimicrob Agents Chemother. 1984 Jul;26(1):94-6 PMID: 6236748
  10. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.
    Antimicrob Agents Chemother. 1983 Apr;23(4):559-64 PMID: 6222695
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
Published
1985-08-00
Pages
308-10
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC180237
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]